Developing RNA-targeting medicines to treat previously incurable diseases

Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders.

WOBURN, Mass., July 10, 2024 — Rgenta Therapeutics, a biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, announced the clearance of its Investigational New Drug application (IND) by the U.S. Food and Drug Administration (FDA) for RGT-61159, which is being developed for the potential treatment of adenoid cystic carcinoma (ACC), colorectal cancer (CRC) and other solid tumors as well as acute myeloid leukemia (AML).

Read more …

Work with us

At Rgenta, our vision is aligned with one goal- to serve patients- by paving the way in precision medicine.


If you are bold, see the possibilities in front of you and strive to be impactful, we want to meet you!